Blog

- Andrew Celentano

AI-engineered nasal spray antiviral platform developed to block flu and COVID-19

Respiratory viruses that have diverse strains and mutate rapidly, such as influenza and COVID-19, are difficult to block perfectly with vaccines alone. To solve this problem, KAIST’s research team has successfully developed an intranasal antiviral platform using AI technology to overcome the existing limitations of interferon-lambda treatments—namely, being weak against heat and disappearing quickly from the nasal mucosa.

Read More »

AZmed Expands Into CT Imaging With CE-Marked AZnod, An AI Tool for Lung Nodule Detection and the First Product in the Rayscan® Line

PARIS, Dec. 15, 2025 /PRNewswire/ — AZmed, one of the leading companies in artificial intelligence (AI) for radiology, announced today the CE marking of AZnod, its first AI tool for computed tomography (CT) within the new Rayscan® product line. This expansion complements AZmed’s existing Rayvolve® AI Suite, extending the company’s portfolio beyond standard X-rays to include advanced CT-based analysis.

Read More »

Scientists develop mini human heart organoid that mimics atrial fibrillation

Though an estimated 60 million people around the world have atrial fibrillation, or A-fib, a type of irregular and often fast heartbeat, it’s been at least 30 years since any new treatments have been developed. This is because researchers haven’t had accurate models of the human heart to study. Thanks to new developments from Michigan State University scientists, that is no longer the case.

Read More »

Peijia Medical Receives NMPA Approval for TaurusTrio Transcatheter Aortic Valve System, Pioneering Treatment for Aortic Regurgitation in China

HONG KONG, Dec. 12, 2025 /PRNewswire/ — Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its TaurusTrio Transcatheter Aortic Valve (TAV) system received approval from the National Medical Products Administration (NMPA) of China on December 11, 2025.

Read More »